Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AstraZeneca < Previous 1 2 3 4 5 6 Next > AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030 August 16, 2023 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial July 27, 2023 From AstraZeneca Via Business Wire Tickers AZN Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial July 03, 2023 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial June 29, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health June 28, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites June 13, 2023 From AstraZeneca Via Business Wire Tickers AZN Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer June 12, 2023 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial June 05, 2023 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors June 05, 2023 From AstraZeneca Via Business Wire Tickers AZN ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care June 05, 2023 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial June 04, 2023 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial June 03, 2023 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial June 02, 2023 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer June 01, 2023 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy May 26, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023 May 25, 2023 From AstraZeneca Via Business Wire Tickers AZN New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD May 23, 2023 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial May 17, 2023 From AstraZeneca Via Business Wire Tickers AZN FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients May 09, 2023 From AstraZeneca Via Business Wire Tickers AZN NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks April 24, 2023 From AstraZeneca Via Business Wire Tickers AZN IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial April 16, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023 April 11, 2023 From AstraZeneca Via Business Wire Tickers AZN Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks March 27, 2023 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer March 09, 2023 From AstraZeneca Via Business Wire Tickers AZN IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer March 09, 2023 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial March 06, 2023 From AstraZeneca Via Business Wire Tickers AZN Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023 March 02, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium February 16, 2023 From AstraZeneca Via Business Wire Tickers AZN TEZSPIRE® approved for self-administration in the US with a new pre-filled pen February 02, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc. January 23, 2023 From AstraZeneca Via Business Wire Tickers AZN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.